PRODUCT
Iambic Therapeutics Enhances AI Suite with “Enchant” for Predictive Preclinical Drug Development
Iambic Therapeutics, AI, Enchant, preclinical predictive powers, drug discovery, clinical success prediction
Roche Revisits Dyno for AAV Technology with $50M Upfront Payment
Roche, Dyno Therapeutics, AAV technology, gene therapy, neurological diseases, strategic partnership
Starboard Value Targets Kenvue for Revitalization Following $1B Stake in Pfizer
Starboard Value, Kenvue, Johnson & Johnson, Pfizer, activist investor, consumer health, pharmaceuticals
Seaport Therapeutics Secures $225M Series B Funding to Revolutionize Neuropsychiatric Medicines
Seaport Therapeutics, Series B funding, neuropsychiatric medicines, Glyph technology platform, clinical-stage pipeline, major depressive disorder, generalized anxiety disorder.
Seaport Therapeutics Secures $225 Million in Oversubscribed Series B Funding
Seaport Therapeutics, Series B funding, neuropsychiatric medicines, Glyph technology platform, biotech investment
FDA Places Clinical Hold on Novavax’s COVID-19-Influenza Combination and Standalone Influenza Vaccine Trials
Novavax, FDA, Clinical Hold, COVID-19, Influenza, Vaccine Trials, Motor Neuropathy
Johnson & Johnson’s Oncology Segment Thrives with Darzalex and Carvykti, Offsetting Stelara Decline
Johnson & Johnson, Darzalex, Carvykti, Stelara, Oncology, Multiple Myeloma, Pharmaceutical Sales
Illumina Introduces MiSeq i100 Series: Simplifying Next-Generation Sequencing with Push-Button Workflows
Illumina, MiSeq i100 Series, Benchtop DNA Sequencer, Push-Button Workflows, Next-Generation Sequencing (NGS), Genomics, DNA Sequencing
BioMarin and CAMP4 Collaborate on RNA-Targeting Therapies for Rare Genetic Diseases
BioMarin, CAMP4, RNA-targeting therapies, genetic diseases, regulatory RNA, RAP Platform, antisense oligonucleotides, ASOs, rare genetic conditions
FDA Panel Recommends Limiting Immunotherapy Access for Stomach and Esophageal Cancer Patients Based on PD-L1 Expression
FDA, Immunotherapy, Stomach Cancer, Esophageal Cancer, PD-L1 Expression, Keytruda, Opdivo, Tevimbra